Key Points
- Director Brian Jg Pereira sold 502,136 shares on Nov. 13 at an average of $2.37 for $1,190,062.32 and had sold 255,026 shares on Nov. 12 at $2.72 for $693,670.72, a combined insider sale of about $1.88M disclosed in an SEC filing.
- PROK shares rose 5.7% to $2.41 on Friday on ~1.34M shares traded; the company has a market cap of $709.2M, a negative P/E of -4.38, and a 52-week range of $0.46–$7.13.
- ProKidney is a clinical-stage biotech whose lead product REACT is in Phase II/III trials for diabetic kidney disease; it reported Q earnings of ($0.12) per share (meeting estimates) with $0.22M revenue, and analysts have a mixed view with a consensus target of $6.25.
ProKidney Corp. (NASDAQ:PROK - Get Free Report) Director Brian Jg Pereira sold 255,026 shares of ProKidney stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $2.72, for a total value of $693,670.72. Following the sale, the director owned 54,333 shares in the company, valued at $147,785.76. This trade represents a 82.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.
Brian Jg Pereira also recently made the following trade(s):
- On Thursday, November 13th, Brian Jg Pereira sold 502,136 shares of ProKidney stock. The shares were sold at an average price of $2.37, for a total value of $1,190,062.32.
ProKidney Price Performance
Shares of NASDAQ PROK traded up $0.13 during mid-day trading on Friday, reaching $2.41. 1,336,204 shares of the company's stock were exchanged, compared to its average volume of 1,643,471. The firm has a 50-day moving average price of $2.81 and a two-hundred day moving average price of $2.13. The firm has a market capitalization of $709.21 million, a price-to-earnings ratio of -4.38 and a beta of 1.75. ProKidney Corp. has a 52 week low of $0.46 and a 52 week high of $7.13.
ProKidney (NASDAQ:PROK - Get Free Report) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.12). The company had revenue of $0.22 million for the quarter, compared to analysts' expectations of $0.04 million. As a group, sell-side analysts forecast that ProKidney Corp. will post -0.57 EPS for the current fiscal year.
Institutional Trading of ProKidney
Several hedge funds and other institutional investors have recently modified their holdings of PROK. JPMorgan Chase & Co. boosted its holdings in ProKidney by 3,024.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,668,642 shares of the company's stock worth $988,000 after buying an additional 1,615,243 shares during the period. Bank of America Corp DE boosted its holdings in shares of ProKidney by 12.4% in the second quarter. Bank of America Corp DE now owns 846,154 shares of the company's stock worth $501,000 after acquiring an additional 93,322 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of ProKidney by 8.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 825,647 shares of the company's stock valued at $723,000 after purchasing an additional 65,860 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of ProKidney during the 2nd quarter valued at $350,000. Finally, UBS Group AG lifted its holdings in ProKidney by 7.0% during the 3rd quarter. UBS Group AG now owns 508,353 shares of the company's stock worth $1,230,000 after purchasing an additional 33,306 shares in the last quarter. Institutional investors own 51.59% of the company's stock.
Wall Street Analysts Forecast Growth
PROK has been the subject of several research analyst reports. Zacks Research lowered shares of ProKidney from a "strong-buy" rating to a "hold" rating in a research note on Monday, August 18th. Weiss Ratings reissued a "sell (d-)" rating on shares of ProKidney in a research report on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $6.25.
Check Out Our Latest Analysis on PROK
ProKidney Company Profile
(
Get Free Report)
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
